S*Bio Develops Singapore's First Clinical Anti-Cancer Drug Candidate

Novel HDAC inhibitor SB939

10-Jul-2006

S*BIO Pte Ltd announced that it has taken a significant step forward in its drug discovery and development efforts as its lead clinical candidate for cancer moves towards the clinic. SB939 is Singapore's first home-grown clinical candidate to be developed as a novel targeted cancer therapy.

S*BIO anticipates that clinical trials of SB939 will commence both in Singapore and in North America in Q1 2007. In preclinical studies, SB939 demonstrates excellent anti-cancer efficacy. SB939 has the potential to be used as an oral therapy for a variety of human haematological malignancies and solid tumours. SB939 belongs to a novel series of targeted small molecule based anti-cancer agents that inhibit histone deacetylases (HDAC), enzymes that are important regulators of pro-apoptotic factors and proteins involved in cell cycle progression and differentiation.

"We are very excited about the success of SB939 and are strongly committed to accelerating its clinical development," commented Dr. Jan-Anders Karlsson, Chief Executive Officer of S*BIO. Moving forward, S*BIO will drive other programs, including next generation HDAC inhibitors and a new type of kinase inhibitors, which are targeted to reach preclinical development by the end of 2006.

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances